Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis: a network meta-analysis of phase 3-4 randomized trials.
What's New
Upadacitinib 30 mg ranked highest in efficacy across all evaluated outcomes among approved systemic therapies for moderate-to-severe atopic dermatitis.
Detailed Summary
A Bayesian network meta-analysis of 33 phase 3-4 RCTs (n=16,334) compared approved systemic targeted therapies for moderate-to-severe atopic dermatitis. Upadacitinib 30 mg consistently showed the highest probability of achieving EASI-75, EASI-90, IGA 0/1, and NRS response, though findings were based primarily on indirect comparisons.
Study Population
Adults with moderate-to-severe atopic dermatitis (n=16,334 across 33 trials)
This research is for informational purposes only — discuss with your doctor before making any changes to your care.
Rivvet may earn a referral fee if you book through this link.
Discussion
Loading comments...
Comments are public. Be respectful and remember: this is not medical advice. Do not share personal health information.